Research
Hormonal
SGLT2 inhibitors lower HbA1c by 0.6-0.8% without increasing hypoglycemia risk when used as monotherapy, but require dose adjustment of insulin/secretagogues when combined.
SGLT2 inhibitors effectively lower blood sugar (HbA1c) by about 0.6-0.8% without causing low blood sugar on their own. If you are also taking insulin or sulfonylureas, your doctor may lower your dose of those medications to prevent hypoglycemia. This makes them a safer option for many patients compared to older drugs.
GoodQualifiesHIGH confidence
SGLT2 inhibitors lower glycated hemoglobin (HbA1c) by 0.6–0.8% (6–8 mmol/mol) without increasing the risk of hypoglycemia... Since glucose reabsorption by SGLT1 is compensatorily enhanced as a result of SGLT2 inhibition, SGLT2 inhibitor monotherapy does not increase the risk of hypoglycemia.
Why this rating
Based on meta-analysis of 45 clinical trials.
Source
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
Yoshifumi Saisho · Diseases · 2020
DOI 10.3390/diseases8020014
narrative_reviewCited 130×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, primarily through hemodynamic effects (osmotic diuresis and natriuresis) rather than glucose-lowering.Strong
- SGLT2 inhibitors promote weight loss and improve metabolic parameters (blood pressure, lipid profile, uric acid) by increasing urinary glucose excretion, resulting in an energy deficit of 240-320 kcal/day.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →